

**API PRODUCT PORTFOLIO**

PRODUCT	INDICATION	API MICRONIZED	CEP/DMF
<b>Arformoterol tartrate<sup>P</sup> polymorph A and D</b>	COPD	√	US-CN DMF
<b>Formoterol fumarate</b>	Asthma and COPD	√	CEP / US-JP-KR-CN DMF
<b>Glycopyrronium bromide<sup>P</sup></b>	COPD	√	CEP / US-CN DMF
<b>Indacaterol maleate<sup>P</sup></b>	Asthma and COPD	√	EU/US DMF
<b>Salmeterol xinafoate<sup>P</sup></b>	Asthma and COPD	√	CEP / US-CN-KR DMF
<b>Tiotropium bromide</b>	COPD	√	CEP / US-CN DMF
<b>Vilanterol trifenate</b>	Asthma and COPD	√	EU DMF

**API PRODUCT PIPELINE**

PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
<b>Abediterol</b>	Asthma and COPD			2023	2023
<b>Aclidinium bromide</b>	COPD	√	√	√	Q3 2021
<b>Batefenterol</b>	COPD			2023	2024
<b>Olodaterol<sup>P</sup></b>	COPD	√	√	√	Q2 2022
<b>Revefenacin</b>	COPD			Q2 2021	Q4 2021
<b>Umeclidinium bromide</b>	COPD	√	√	Q2 2021	Q4 2021

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

THERAPEUTIC AREA	PRODUCT	INDICATION	API MICRONIZED	CEP/DMF
Antiallergics	Loratadine <sup>P</sup>	Allergy	√	JP DMF
Antiarrhythmics	Dronedaron <sup>P</sup>	Atrial fibrillation & general arrhythmia		DMF
Antiasthmatics, COPD and respiratory diseases	Arformoterol tartrate <sup>P</sup> polymorph A and D	COPD		US-CN DMF
	Formoterol fumarate	Asthma and COPD	√	CEP/US-JP-KR-CN DMF
	Glycopyrronium bromide <sup>P</sup>	COPD	√	CEP/ US-CN DMF
	Indacaterol maleate <sup>P</sup>	Asthma and COPD	√	EU/US DMF
	Montelukast sodium <sup>P</sup>	Asthma, allergic & seasonal rhinitis		EU-JP DMF
	Salmeterol xinafoate <sup>P</sup>	Asthma and COPD	√	CEP/ US-CN-KR DMF
	Tiotropium Bromide	COPD	√	CEP/US-CN DMF
	Vilanterol Trifenatate	Asthma and COPD	√	EU DMF
Antiemetics	Aprepitant	Emesis		US DMF
	Granisetron base <sup>P</sup>	Emesis		US DMF
	Granisetron hydrochloride <sup>P</sup>	Emesis		CEP/ US-JP-KR DMF
	Ondansetron base <sup>P</sup>	Emesis	√	EU-US DMF
	Ondansetron hydrochloride <sup>P</sup>	Emesis	√	CEP/US DMF
Antifungals	Fluconazole <sup>P</sup>	Antifungal		CEP/US-KR DMF
Antihypertensive	Carvedilol <sup>P</sup>	Hypertension, angina, heart failure		JP DMF
	Enalapril maleate <sup>P</sup>	Hypertension		CEP/KR DMF
	Imidapril	Hypertension		EU DMF
	Nifedipine	Hypertension	√	CEP/DMF
Antimigrainics	Eletriptan HBr <sup>P</sup>	Migraine	√	JP DMF
	Rizatriptan benzoate <sup>P</sup>	Migraine	√	EU-US DMF
	Zolmitriptan <sup>P</sup>	Migraine	√	EU-US DMF
Antipsychotics	Asenapine maleate <sup>P</sup>	Schizophrenia and acute mania	√	JP DMF
	Olanzapine <sup>P</sup>	Schizophrenia, psychosis		EU-US- DMF
	Quetiapine hemifumarate <sup>P</sup>	Schizophrenia, psychosis		JP-KR DMF
	Risperidone <sup>P</sup>	Schizophrenia, psychosis	√	CEP/US-KR DMF
Antithrombotics	Prasugrel base <sup>P</sup>	Prophylaxis and therapy of thrombosis		EU DMF
	Rivaroxaban	Thrombosis. Stroke		DMF
Spasmolytic	Otilonium bromide	Irritable bowel syndrome		EU DMF

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

THERAPEUTIC AREA	PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
Antiasthmatics, COPD and respiratory diseases	<b>Abediterol</b>	Asthma and COPD			2023	2023
	<b>Acclidinium bromide</b>	COPD	√	√	√	Q3 2021
	<b>Batefenterol</b>	COPD			2023	2024
	<b>Olodaterol<sup>P</sup></b>	COPD	√	√	√	Q2 2022
	<b>Revefenacin</b>	COPD			Q2 2021	Q4 2021
	<b>Umeclidinium bromide</b>	COPD	√	√	Q2 2021	Q4 2021
Antihypertensive	<b>Clevidipine<sup>P</sup></b>	Hypertension	√	√	√	Q2 2021
Antiparkinson	<b>Benserazide</b>	Parkinson's disease			Q2 2021	Q1 2022
	<b>Tetrabenazine</b>	Huntington's disease chorea and Tardive dyskinesia	√	√	√	√
Antipsychotics	<b>Olanzapine pamoate</b>	Schizophrenia, psychosis	√	√	√	Q4 2021
	<b>Paliperidone Palmitate</b>	Schizophrenia, bipolar mania				
Other disorders	<b>Tafamidis meglumine</b>	Transthyretin amyloidosis	√	Q3/Q4 2020	√	Q3 2021
	<b>Tolvaptan</b>	Hyponatremia	√	√	Q2 2021	Q1 2022

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular, these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.